Expert Perspectives & Insights into CAR T-cell Therapy in Relapsed / Refractory Acute Lymphoblastic Leukemia

home / peer-exchange / expert-perspectives-and-insights-into-car-t-cell-therapy-in-rrall

Elias Jabbour, MD; Evandro D. Bezerra, MD; Lori Muffly, MD; Jae H. Park, MD, and Gregory W. Roloff, MD,review the role of CAR T-cell therapy\ for relapsed/refractory acute lymphoblastic leukemia, address adverse event management and supportive care, and highlight significant updates presented at the American Society of Clinical Oncology and European Hematology Association 2024 conferences.

EP. 1: Overview of CAR T-cell Therapies in R/R B-cell ALL

By Elias Jabbour, MD
Evandro D. Bezerra, MD

June 27th 2024

Evandro D. Bezerra, MD, provides an overview of current CAR T-cell therapies for relapsed/refractory B-cell acute lymphoblastic leukemia and explores emerging CAR T products under investigation.

EP. 2: CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel

By Elias Jabbour, MD
Evandro D. Bezerra, MD

June 27th 2024

Dr. Lori Muffly explains the general mechanism of action in CAR T-cell therapy and compares the distinct features of Brexucabtagene autoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtagene autoleucel (Obe-cel).